ATEC Alphatec Holdings, Inc. gains 75% Mar 22, 2019

Alphatec Holdings, Inc., a medical technology company, focuses on the design, development, manufacture, and marketing of products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar, and intervertebral regions of the spine, as well as covers various spinal disorders and surgical procedures. The company offers cervical and cervico-thoracic products, including Trestle Luxe Anterior Cervical Plate System, Solanas Posterior Cervico/Thoracic Fixation System and Avalon Occipital Plate, and Pegasus Anchored Cervical Interbody system. It also provides thoracolumbar fixation products, such as Arsenal Degenerative System, Arsenal CBx Cortical Bone Fixation System, Zodiac Degenerative Spinal Fixation System, Zodiac Deformity Spinal Fixation System, and OsseoScrew Spinal Fixation System. In addition, the company offers spinal spacers comprising Battalion Universal Spacer System, Novel PEEK and Titanium Spinal Spacers, and Alphatec Solus Locking ALIF Spinal Spacer; and MIS Products consisting of Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System. Further, it offers biologics, such as Neocore Osteoconductive Matrix, a synthetic scaffold for the regeneration of bone. The company sells its products through direct sales representatives and independent sales agents in the United States, as well as through independent distributors internationally. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.http://www.priceseries.com/trade/ATEC-Alphatec-Holdings-Inc-stock-gains-75-percent-a-Trade-Record-by-priceSeries-2019022220190322.html

AGRX Agile Therapeutics, Inc. gains 28% Mar 22, 2019

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.http://www.priceseries.com/trade/AGRX-Agile-Therapeutics-Inc-stock-gains-28-percent-a-Trade-Record-by-priceSeries-2019030820190322.html

ACHV Achieve Life Sciences, Inc. gains 16% Mar 22, 2019

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The company is headquartered in Bothell, Washington.http://www.priceseries.com/trade/ACHV-Achieve-Life-Sciences-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019031420190322.html

ACHN Achillion Pharmaceuticals, Inc. gains 34% Mar 22, 2019

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, a drug candidate that is delivered topically or locally; and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.http://www.priceseries.com/trade/ACHN-Achillion-Pharmaceuticals-Inc-stock-gains-34-percent-a-Trade-Record-by-priceSeries-2019020820190322.html

WVE WAVE Life Sciences Ltd. gains 19% Mar 20, 2019

Preclinical biotech developing optimized RNA therapies for rare diseases.http://www.priceseries.com/trade/WVE-WAVE-Life-Sciences-Ltd-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2019022220190320.html

TGNA TEGNA Inc. gains 20% Mar 20, 2019

TEGNA Inc. engages in media and digital businesses in the United States. The company operates in two segments, Media and Digital. It operates 46 television stations that produce local programming, such as news, sports, and entertainment. The company also operates Cars.com, an online destination for automotive consumers that offers information about car shopping, selling, and servicing; CareerBuilder, which provides human capital solutions, such as employment data and labor market analysis software, talent management software, and other advertising and recruitment solutions; and G/O Digital that provides digital marketing services for local businesses. The company was formerly known as Gannett Co., Inc. and changed its name to TEGNA Inc. in June 2015. TEGNA Inc. was founded in 1906 and is headquartered in McLean, Virginia.http://www.priceseries.com/trade/TGNA-TEGNA-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2019021120190320.html

SEE Sealed Air Corporation gains 24% Mar 20, 2019

Sealed Air Corporation provides food safety and security, facility hygiene, and product protection solutions worldwide. The company's Food Care segment offers integrated system solutions that incorporate equipment systems into customers' operations; and packaging equipment for loading, filling and dispensing, and retort and aseptic processing conditions. It also provides graphic design, printing, training, field quality assurance, and remote diagnostics services; and clean-in-place and open plant systems that integrate cleaning chemicals, lubricants, floor care equipment, and cleaning and dispensing tools. This segment offers its products under the Cryovac Grip & Tear, Cryovac Darfresh, Cryovac Mirabella, Simple Steps, Secure Check, Enduro Power, and Optidure brands; and the Cryovac and Diversey trademarks. Its Diversey Care segment offers products and dispensing systems for hard surface cleaning, disinfecting and sanitizing, hand washing, deodorizing, mechanical and manual ware washing, hard surface and carpeted floor cleaning systems, floor cleaning robots, cleaning tools and utensils, and fabric care for professional laundry applications under the Diversey, TASKI, and Intellibot brands. The company's Product Care segment provides packaging solutions for cushioning, void fill, positioning/block-and-bracing, surface protection, retail display, containment, and dunnage needs under the Bubble Wrap and AirCap, Cryovac, Shanklin, Instapak, Jiffy, and Korrvu brands, as well as I-Pack systems and e-Cube systems. Its Other segment offers flexible packaging materials for medical and drug delivery devices; specialty component films for ostomy and colostomy bags; and PVC free films for packing pharmaceutical solutions. The company serves food and beverage processing, food service, retail, healthcare and industrial, and commercial and consumer application markets. Sealed Air Corporation was founded in 1960 and is headquartered in Charlotte, North Carolina.http://www.priceseries.com/trade/SEE-Sealed-Air-Corporation-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2019011020190320.html

SBGI Sinclair Broadcast Group, Inc. gains 19% Mar 20, 2019

Sinclair Broadcast Group, Inc. operates as a television broadcasting company in the United States. It owns or provides various programming, operating, or sales services to television stations. The company broadcasts free over-the-air programming, such as network provided programs, locally-produced news, local sporting events, programming from program service arrangements, syndicated entertainment programs, and internally originated programming to television viewing audiences in the communities through various local television stations. As of February 22, 2017, it owns, operates, and/or provides services to 173 television stations in 81 markets, which broadcast 505 channels. The company also offers digital agency services; and technical services to the broadcast industry, as well as designs and manufactures broadcast systems, including transmitters and antennas. In addition, it provides sign design and fabrication, and security alarm monitoring and bulk acquisition services; and invests in various real estate ventures, including developmental land, and operating commercial and multi-family residential real estate properties and apartments, as well as private equity and structured debt/mezzanine financing investment funds. Sinclair Broadcast Group, Inc. was founded in 1986 and is headquartered in Hunt Valley, Maryland.http://www.priceseries.com/trade/SBGI-Sinclair-Broadcast-Group-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2019021120190320.html

RARX Ra Pharmaceuticals Inc gains 16% Mar 20, 2019

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Its peptide chemistry platform delivers enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. The company's lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It also develops Factor D inhibition for age-related macular degeneration and geographic atrophy; Oral C5 inhibitor for refractory generalized myasthenia gravis, lupus nephritis, and central nervous system (CNS) diseases; C1s inhibition for autoimmune/CNS diseases. The company has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.http://www.priceseries.com/trade/RARX-Ra-Pharmaceuticals-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019030720190320.html

NYT New York Times Company (The) gains 46% Mar 20, 2019

The New York Times Company, together with its subsidiaries, provides news and information for readers and viewers across various platforms worldwide. The company provides The New York Times (The Times), a daily and Sunday newspapers in the United States, as well as international edition of The Times; and operates the NYTimes.com Website. It also transmits articles, graphics, and photographs from The Times and other publications to approximately 2000 newspapers, magazines, and Websites; and offers product licensing, book development, news digests, and rights and permissions, as well as is involved in online retail store business. In addition, the company engages in NYT Live business, a platform for its live journalism; and digital archive distribution, which licenses electronic archive databases to resellers of that information in the business, professional, and library markets. Further, it develops mobile applications, including NYT cooking, Crossword, and others; and operates product review and recommendation Websites that serve as a guide to technology gear, home products, and other consumer goods. The New York Times Company was founded in 1896 and is headquartered in New York, New York.http://www.priceseries.com/trade/NYT-New-York-Times-Company-The-stock-gains-46-percent-a-Trade-Record-by-priceSeries-2019010720190320.html